{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04672356",
      "orgStudyIdInfo": {
        "id": "CIBI939A102(Ia)"
      },
      "organization": {
        "fullName": "Innovent Biologics (Suzhou) Co. Ltd.",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer",
      "officialTitle": "An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-06",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-01-25",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-01-01",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2023-06-01",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-12-13",
      "studyFirstSubmitQcDate": "2020-12-16",
      "studyFirstPostDateStruct": {
        "date": "2020-12-17",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-06-18",
      "lastUpdatePostDateStruct": {
        "date": "2023-06-22",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Innovent Biologics (Suzhou) Co. Ltd.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safety of recombinant fully human anti-TIGIT antibody (IBI939) in combination with recombinant fully human anti-programmed cell death receptor 1 (PD-1) antibody (sintilimab) in subjects with advanced lung cancer."
    },
    "conditionsModule": {
      "conditions": [
        "Advanced Lung Cancer"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SEQUENTIAL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 19,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Phase Ia: IBI939 in combination with Sintilimab",
          "type": "EXPERIMENTAL",
          "description": "IBI939 10mg/kg combination with Sintilimab",
          "interventionNames": [
            "Biological: IBI939",
            "Biological: Sintilimab"
          ]
        },
        {
          "label": "Phase Ia:IBI939 in combination with Sintilimab",
          "type": "EXPERIMENTAL",
          "description": "IBI939 20mg/kg combination with Sintilimab",
          "interventionNames": [
            "Biological: IBI939",
            "Biological: Sintilimab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "IBI939",
          "description": "IBI939 injection",
          "armGroupLabels": [
            "Phase Ia: IBI939 in combination with Sintilimab",
            "Phase Ia:IBI939 in combination with Sintilimab"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Sintilimab",
          "description": "Sintilimab injection",
          "armGroupLabels": [
            "Phase Ia: IBI939 in combination with Sintilimab",
            "Phase Ia:IBI939 in combination with Sintilimab"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Adverse Events",
          "timeFrame": "3 months"
        },
        {
          "measure": "Recommended Phase II Dose(RP2D)",
          "timeFrame": "2 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Objective response rate(ORR)",
          "description": "Proportion of subjects with complete response (CR) or partial response (PR).",
          "timeFrame": "6 months"
        },
        {
          "measure": "Disease Control Rate(DCR)",
          "description": "Proportion of subjects with complete response (CR), partial response (PR), or stable disease (SD).",
          "timeFrame": "6 months"
        },
        {
          "measure": "Time to Objective Response (TTR)",
          "description": "Time from randomization to first objective tumor response (CR or PR).",
          "timeFrame": "6 months"
        },
        {
          "measure": "Duration of Response (DoR)",
          "description": "The time from the first documented objective tumor response (CR or PR) to objective disease progression (PD) or death.",
          "timeFrame": "6 months"
        },
        {
          "measure": "Progression-free survival(PFS)",
          "description": "The time from randomization to the first occurrence of objective disease progression or death",
          "timeFrame": "6 months"
        },
        {
          "measure": "Area under the plasma concentration-time curve (AUC)",
          "timeFrame": "24 hours"
        },
        {
          "measure": "Maximum concentration (Cmax)",
          "timeFrame": "24 hours"
        },
        {
          "measure": "Trough concentration (Cmin)",
          "timeFrame": "24 hours"
        },
        {
          "measure": "Clearance (CL)",
          "timeFrame": "24 hours"
        },
        {
          "measure": "Volume of distribution (V)",
          "timeFrame": "24 hours"
        },
        {
          "measure": "Half-life (t1/2)",
          "timeFrame": "24 hours"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Signed the Informed Consent Form;\n2. Male or female ≥ 18 and≤75 years of age;\n3. Life expectancy ≥ 12 weeks;\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score is 0 or 1\n5. Have at least 1 lesion (not previously irradiated) with an accurately measured longest diameter ≥ 10 mm by computed tomography (CT) or magnetic resonance imaging (MRI) (intravenous contrast agent is preferred) at baseline (except lymph nodes which must have short axis ≥ 15 mm) according to RECIST V1.1 and lesions amenable to repeated accurate measurements.\n6. Histologically or cytologicallyconfirmed non-small cell lung or small cell lung cancer\n\nExclusion Criteria:\n\n1. Previous exposure to immune-mediated therapy; previous use of antitumor vaccine;\n2. Received the last anti-tumor therapy within 4 weeks prior to the first dose of study drug;\n3. Received any investigational agent within 4 weeks prior to the first dose of study drug;\n4. Received systemic treatment with Chinese herbal medicine indicated for cancer or drugs used for immunoregulation (including thymosin, interferon, interleukin, except for local use for pleural effusion) within 2 weeks before the first dose;\n5. Are participating in another interventional clinical study, or observational (non-interventional) clinical study or in the follow-up phase of an interventional study;",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ying Cheng",
          "affiliation": "Jilin Province Cancer Hospital",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Jilin Province Cancer Hospital",
          "city": "Jilin",
          "country": "China",
          "geoPoint": {
            "lat": 43.84652,
            "lon": 126.5608
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-19"
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000632826",
          "term": "sintilimab"
        }
      ]
    }
  },
  "hasResults": false
}